Non-Hodgkin's Lymphoma
News
Maintenance Rituxan® Is Safe for Follicular Lymphoma
(07/03/2008)
Continued treatment for up to two years with Rituxan® (rituximab) is a safe therapeutic approach for the treatment of follicular lymphoma. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
(05/13/2008)
Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
(05/08/2008)
Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
Treanda® Included in NCCN Guidelines for CLL and NHL
(05/05/2008)
The chemotherapy agent Treanda® (bendamustine) has been added to the treatment guidelines of the National Comprehensive Cancer Network (NCCN) as an accepted treatment option for chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
Differences in IMRT Radiation Doses May Complicate Study Results in Lymphomas
(04/07/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in lymphomas difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
More
Non-Hodgkin's Lymphoma
Cancer News...